

Regenerative Medicine: From Wound Healing to Anti-Aging



INDUSTRY: Wound Care, Dermatology, Aesthetics, Anti-Aging

TECHNOLOGY: Sound Induced Morphogenesis

FOUNDED: Founded in 2019 in Switzerland, Mimix will incorporate Mimix AWC spin-off in Florida in 2024.

LOCATION: Florida, USA

KEY SHAREHOLDERS: AO foundation, Heraeus, Asia Jetway PTE

FLAGSHIP PRODUCT: FastSkin®

TARGET MARKETS:

- Chronic Wound Care : \$5.7 billion
- Dermatology: \$34 billion by 2027
- Aesthetics: \$87 billion by 2030

EXPANSION GOALS:

Enter U.S Wound Care Market by Q2/2025 with future applications in dermatology and aesthetics

FUNDRAISING :

- \$6.3 million Seed A&B raised
- **\$14 million round open**

IP: 3 patent families (method, device and application)

EXECUTIVE TEAM:

- Marc Thurner - CEO, Founder of RegenHu & Former CEO
- Tanya Rhodes - CSO, Former Vice-President of Innovation at Smith & Nephew
- Andreas Scheidegger - CTO, Technology Manager in Biopharma

+8 team members

Company Overview

Mimix AWC is at the forefront of a technological revolution in enhanced regenerative medicine with its proprietary Sound-Induced Morphogenesis technology.

Our flagship product, FastSkin®, is positioned to disrupt the \$50 billion U.S. wound care market, particularly in chronic wound management. Following a successful market entry in wound care, Mimix AWC plans to expand its innovative platform technology into the rapidly growing dermatology and aesthetics markets. These sectors represent significant additional revenue opportunities, with the potential to transform the way both medical professionals and consumers approach skin health and aesthetics.

Technology

Sound-Induced Morphogenesis (SIM) mirrors nature's design strategy by organizing cells into controlled, high-density biological patterns, enhancing communication and accelerating tissue formation. This simple, versatile technology adapts across wound healing, skin regeneration, and advanced tissue engineering, positioning Mimix for seamless expansion into diverse therapeutic areas.

Market

Chronic wounds, skin health, and aesthetic care are critical areas of unmet need in medicine, posing significant challenges for both patients and healthcare providers.

- Chronic Wounds: Millions suffer from non-healing wounds like diabetic foot ulcers, leading to severe complications and costing over \$50 billion annually in the U.S.
 - **Explosion of diabetes incidence rate: people under age 20 with type 2 diabetes may increase 675% by 2060 leading to amputation and severe complications**
- Dermatology: Conditions like scars, keloids, and age-related skin degeneration need advanced solutions.
- Aesthetics: Rising demand for skin rejuvenation and anti-aging treatments






Mimix's SIM platform, powered by FastSkin® and future innovations, delivers scalable healing, regeneration, and rejuvenation solutions that surpass current technologies and create new reimbursement opportunities through both independent approaches and enhancements to existing products.

Strategy to become a Market Leader

We are implementing a phased strategy to establish ourselves as a leading player in the market:

- **Step 1: Chronic Wound Care (\$5.7 billion market)** – FastSkin® utilizes SIM technology for optimizing cellular organization for effective healing of complex wounds. FastSkin®, a simplified, ready-to-use kit, is designed for point-of-care use with high reimbursement eligibility.
- **Step 2: Dermatology (\$34 billion market by 2027)** – SIM technology enables applications in scar treatment, skin regeneration, and anti-aging, opening new therapeutic possibilities for dermatological conditions.
- **Step 3: Aesthetics (\$87 billion market by 2030)** – FastSkin® can be adapted for skin rejuvenation, post-procedure recovery, and hair regeneration, positioning mimix to capture high-margin opportunities within this rapidly growing sector.

Large Initial US Market Opportunity in Chronic Wound Care

 <p>Innovative product to promote natural healing</p>	 <p>Eligible to Highest reimbursement codes</p>	 <p>Cover the entire advanced wound care indication arena</p>
 <p>FDA clearance 510(k) by Q2/2025</p>	 <p>Major opportunity thanks to recent changes in reimbursement landscape in CTPs (G Code)</p>	

Peak Revenue Opportunity at Stage 1

Potential \$5.7bn revenue opportunity with high gross margin

2 M

DFU patients are left without solutions (Wagner 2 and more)

X 900\$ per unit

X 8 estimated usage out of 20 permissible (G0465)

X 10% Market penetration

= \$1.4bn

4 M

Currently addressable patients for VLU & PU.

X 600\$ per unit

X 8 estimated usage out of 10 permissible (G0460)

X 10% Market penetration

= \$1.9bn

5 M

Currently addressable patients for non-healing surgical & traumatic wounds

X 600\$ per unit

X 8 assumed usage out of 10 permissible (G0460/CPT)

X 10% Market penetration

= \$2.4bn

DFU= Diabetic Foot Ulcer

VLU= Venous Leg Ulcer

PU=Pressure Ulcer

Funding

A total of \$6.3 million has been invested to date in FastSkin® Treatment. The main investors in are Heraeus, the AO Foundation, and Asia Jetway PTE.

We are seeking \$14 million investment by Q2/2025

Use of proceeds :

- Clinical Investigations broadening indication arenas (VLU, PI, surgical wounds)
- PMCF- Study
- multi-site RCTs /Health Technology Assessment
- US Pilot Market
- Product improvement / portfolio design
- Foreground IP
- Market clearance in China, EU & Middle East
- Marketing internationalization (EU, Asia Pacific, Middle East)
- Sales force development

Willing to join the journey? Contact us



Marc Thurner – Founder & CEO

marc.thurner@mimixbio.com

+41 (79) 369 51 90



Tanya Rhodes

Chief Strategic Officer

tanya.rhodes@mimixbio.com

+1 (727) 458-4291